According to a new report Europe Companion Diagnostics Market, published by KBV research, the Europe Companion Diagnostics Market would witness market growth of 18.1% CAGR during the forecast period (2019-2025).
The Germany market dominated the Europe Colorectal Cancer Companion Diagnostics by Country in 2018, growing at a CAGR of 18 % during the forecast period. The UK market is expected to witness a CAGR of 17.7% during (2019 - 2025). Additionally, The France market is expected to witness a CAGR of 20.3% during (2019 - 2025).
The Oncology market dominated the France Companion Diagnostics Market by Indication in 2018, growing at a CAGR of 20.8 % during the forecast period. The Neurology market is expected to witness a CAGR of 18% during (2019 - 2025).
The Polymerase Chain Reaction (PCR) market dominated the Italy Companion Diagnostics Market by Technology in 2018, growing at a CAGR of 18.9 % during the forecast period. The Immunohistochemistry market is expected to witness a CAGR of 17.6% during (2019 - 2025).
Full Report:https://www.kbvresearch.com/europe-companion-diagnostics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the mentioned countries. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Agilent Technologies, Inc., Almac Group, ARUP Laboratories, Inc., Abbott Laboratories (Abbott Laboratories Molecular, Inc.), Danaher Corporation, Thermo Fisher Scientific, Inc., Hologic, Inc., Novartis AG, Illumina, Inc., Qiagen N.V.
By Technology
By Indication
By Cancer Type
By Country
Companies Profiled
Unique Offerings from KBV Research
Unique Offerings 
